Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency
The study aims to investigate the prevalence of genetic polymorphisms in adults with iron deficiency and anemia, and the responses to two different treatments: iron sulphate and a composite herbal medicine (Hibiscus sabdariffa plus Centella asiatica). The main outcome will be hemoglobin, measured before and after 6 weeks.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Prevalence of Genetic Polymorphisms of DMT1 and Ferroportin Enzymes in Adults With Anemia by Iron Deficiency, and Its Influence on the Efficacy of Conventional and Herbal Treatments|
- Hemoglobin [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Hemoglobin will be measured before treatment and after 6 weeks of treatment
|Study Start Date:||January 2012|
|Study Completion Date:||March 2013|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
|Active Comparator: Iron||
Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
Drug: Herbal medicine
Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01414374
|Laboratorio M. F. Teixeira|
|Monte Santo de Minas, Minas Gerais, Brazil|